BPMC - ブル―プリント・メディシンズ （Blueprint Medicines Corporation）BPMCのニュース
Q3 2023 Earnings Estimate for Blueprint Medicines Co. Issued By Wedbush (NASDAQ:BPMC) 2023/05/29 05:38:42 The AM Reporter
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities researchers at Wedbush boosted their Q3 2023 EPS estimates for shares of Blueprint Medicines in a report issued on Wednesday, May 24th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($2.39) per share for the quarter, up from their prior estimate of […]
Blueprint Medicines Co. Expected to Post Q2 2023 Earnings of ($2.45) Per Share (NASDAQ:BPMC) 2023/05/26 05:34:47 The AM Reporter
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities research analysts at Wedbush boosted their Q2 2023 earnings per share (EPS) estimates for Blueprint Medicines in a report released on Tuesday, May 23rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($2.45) for the quarter, up from […]
Citi maintains Blueprint Medicines Corp at ''sell'' with a price target of $46.00 2023/05/24 07:47:41 Investing.com
https://www.investing.com/news/pro/blueprint-medicines-corp-receives-investment-bank-analyst-rating-update-3089361
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit''s Future 2023/05/23 19:03:31 Benzinga
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC ) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for Latest … Full story available on Benzinga.com
FDA OKs Blueprint Medicines'' Blood Disorder Drug As First Treatment For SM Patients 2023/05/23 17:55:22 Benzinga
The U.S. Food and Drug Administration (FDA) approved Blueprint Medicines Corporation''s (NASDAQ: BPMC ) Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM) . Systemic mastocytosis (SM) is a rare hematologic disorder. ISM represents the vast majority of SM cases, and Ayvakit is now available for adults with ISM at the recommended dose of 25 mg once daily. Ayvakit was designed to potently and selectively inhibit KIT D816V, the primary underlying driver of the disease. Ayvakit … Full story available on Benzinga.com
Blueprint Medicines PT Lowered to $115 at Raymond James 2022/08/02 16:51:02 Investing.com
https://www.investing.com/news/pro/blueprint-medicines-pt-lowered-to-115-at-raymond-james-432SI-2860818
Blueprint Medicines Corporation''s (BPMC) CEO Kate Haviland on Q2 2022 Results - Earnings Call Transcript 2022/08/02 15:31:04 Seeking Alpha
Blueprint Medicines Corporation (NASDAQ:NASDAQ:BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 A.M.
BPMC stock climbs ahead of key data readout despite 2Q miss (NASDAQ:BPMC) 2022/08/02 14:52:27 Seeking Alpha
Shares of oncology focused Blueprint Medicines (BPMC) surged ~13% in the morning hours Tuesday despite lower-than-expected financials for 2Q 2022 as management outlined plans to report…
Blueprint Medicines: Q2 Earnings Insights 2022/08/02 11:39:56 Benzinga
Blueprint Medicines (NASDAQ: BPMC ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus … Full story available on Benzinga.com